

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Joseph T. Strupczewski et al

Application No.: 09/708,475

Filed: November 9, 2000

Title: **HETEROARYLPYPERIDINES, AND
THEIR USE AS ANTIPSYCHOTICS
AND ANALGETICS**

Examiner: Brenda L. Coleman

Art Unit: 1624



I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

6-13-02

Date of Deposit

Barbara E. Kurys
Signature

Commissioner for Patents
Washington, D.C. 20231

Sir:

RECEIVED

JUN 28 2002

Transmitted herewith is an amendment in the above-identified application.

☒ No additional fee is required.

TECH CENTER 1600/2900

The fee has been calculated as shown below.

| (1) | (2) CLAIMS REMAINING AFTER AMENDMENT* | (3) | (4) HIGHEST NUMBER PREVIOUSLY PAID FOR** / *** | (5) PRESENT EXTRA | (6) RATE | (7) ADDITIONAL FEE |
|---|--|-------|---|-------------------------|-------------|--------------------------|
| TOTAL CLAIMS | 113 | MINUS | 115 | 0 | 18.00 | 0 |
| INDEPENDENT CLAIMS | 20 | MINUS | 20 | 0 | 84.00 | 0 |
| MULTI-DEPENDENT CLAIMS(S), Per Application (280.00) | | | | | | |
| TOTAL AMENDMENT FEE FOR THIS AMENDMENT → | | | | | | \$0.00 |

* If the entry in Column 2 is less than the entry in Column 4, write "0" in Column 5.

** If the "Highest Number Previously Paid For" in Total Claims is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" in (Independent Claims is less than 3, write "3" in this space.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. 1.16 which may be required by this paper or credit any overpayment to Account No. 18-1982. Two duplicate copies of this paper are enclosed.

Respectfully submitted,

Barbara E. Kurys
Barbara E. Kurys, Reg. No. 34,650
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626

Aventis Docket No. 2489.0028-12